Our Team
Our Founders
Stephen Hajduk, PhD
Founder & CSO
Extensive scientific track record spanning 47 years with over 100 publications on African Trypanosomes, including pioneering studies on ApoL1 toxicity in these parasites.
Eric DeJesus, PhD
Founder & CEO
Conceptualized and initially investigated ApoL1 as a therapeutic against human disease in 2010, with proven scientific track record of publications on ApoL1 toxicity.
Michael Cipriano, PhD
Founder & Vice President R&D
Conceptualized targeting ApoL1 with a bispecific antibody guided system, bringing a strong background in cell biology, bioinformatics, research study design, and data analysis.
Our Scientific Advisors
Brian Longstreet
Business Advisor
CEO and Co-Founder of Exolvo Biosciences; biotech leader with prior leadership roles at Merck and Schering-Plough, driving early-stage innovation.
Ajay L. Nooka, MD MPH
Clinical Advisor, Myeloma
Myeloma specialist and clinical research leader at Emory's Winship Cancer Institute, advancing innovative trials for plasma cell disorders.
Gregory B. Lesinski, PhD, MPH
Translational Science Advisor, Oncology
Professor and Vice Chair for Basic Research, Department of Hematology and Medical Oncology, and Associate Director for Basic Research at Emory's Winship Cancer Institute advancing immune-oncology and translational cancer research.
Vikas A. Gupta, MD, PhD
Clinical and Translational Science Advisor, Oncology
Vikas Gupta, MD, PhD — Assistant Professor of Hematology and Medical Oncology at Emory University; board-certified hematologist-oncologist advancing myeloma and immunotherapy research.
Serguei V Kozlov, PhD, MBA, PMP
Translational Science Advisor, Animal Models
Expert in GEMM-based preclinical oncology, leading translational in vivo model development at Frederick National Lab.